ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Ceralasertib is on this study

  • The record lists it as a treatment, written “Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 5:17 AM UTC“With olaparib, against olaparib alone, in breast cancer”
  • The role rule says the same.
  • So Ceralasertib's page lists this study under “Testing it”.
4 links1 made here, not in the record6 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03330847To Assess Safety andEfficacy of AgentsTargeting DNA Damage RepairWith Olaparib VersusOlaparib Monotherapy.AstraZenecaPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 14 · ClinicalTrials.gov record · Version of 2026-10-14Version of 2026-10-14CONDITIONSTriple Negative Breast Neop…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSCeralasertibEntry “Ceralasertib 160 mg OD + olapa…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAdavosertibEntry “Adavosertib 150 mg BD + olapar…›Nov 18 · Rule based · TestedTestedOlaparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · partnerBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 14 · changes seen, not judgments
Nov 3CeralasertibClaude Opus 5.5TestedCurrent
Nov 3Olaparibmade hereClaude Opus 5.5Background · partnerCurrent
Nov 14Triple Negative Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18CeralasertibRule based · role ruleTestedAgrees
Nov 18AdavosertibRule based · role ruleTestedCurrent
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.